



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

What Have Advances in Transcriptomic Technologies Taught us About Human White Matter Pathologies?

Citation for published version:

Jaekel, S & Williams, AC 2020, 'What Have Advances in Transcriptomic Technologies Taught us About Human White Matter Pathologies?', *Frontiers in Cellular Neuroscience*, vol. 14, 238.
<https://doi.org/10.3389/fncel.2020.00238>

Digital Object Identifier (DOI):

[10.3389/fncel.2020.00238](https://doi.org/10.3389/fncel.2020.00238)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Frontiers in Cellular Neuroscience

Publisher Rights Statement:

This is the author's final peer-reviewed manuscript as accepted for publication.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



What do single cell technologies teach us about human white matter pathologies?

Sarah Jaekel^{1*}, Anna Williams¹

¹Centre for Regenerative Medicine, University of Edinburgh, United Kingdom

Submitted to Journal:
Frontiers in Cellular Neuroscience

Specialty Section:
Non-Neuronal Cells

Article type:
Review Article

Manuscript ID:
565220

Received on:
24 May 2020

Revised on:
23 Jun 2020

Frontiers website link:
www.frontiersin.org

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Author contribution statement

S.J. and A.W. wrote and edited the manuscript. S.J. also designed and prepared the figures.

Keywords

single cell transcriptomics, single nuclei transcriptomics, human neuropathology, White matter (WM), Multiple sclerosis, RNA-Seq - RNA sequencing, "omics" approaches

Abstract

Word count: 169

For a long time, post-mortem analysis of human brain pathologies has been purely descriptive, limiting insight into the pathological mechanisms. However, starting in the early 2000's, next generation sequencing and the routine application of bulk RNA-sequencing and microarray technologies has revolutionized the usefulness of post-mortem human brain tissue. This has allowed many studies to provide novel mechanistic insights into certain brain pathologies, albeit at a still unsatisfying resolution, with masking of lowly expressed genes and of regulatory elements in different cell types. The recent rapid evolution of single cell technologies has now allowed researchers to shed light on human pathologies at a previously unreached resolution revealing further insights into pathological mechanisms that will open the way for development of new strategies for therapies. In this review, we will give an overview of the incremental information that single cell technologies have given us for human white matter pathologies, summarize which single cell technologies are available and speculate where these novel approaches may lead us for pathological assessment in the future.

Contribution to the field

This review article gives an overview of the use of modern "omics" approaches in the context of human white matter brain pathologies and how these have contributed to our understanding of disease, with a special focus on novel single cell and single nuclei technologies. As the use of these technologies in human brain tissue has only started to emerge recently and are developing at a rapid speed, this article summarizes very recent work including many papers still in preprint at the forefront of this science. We give an overview of different single cell/single nuclei technologies and possible validation techniques and discuss the advantages and limitations from an experimenter point of view. Hence, the article explains single cell technologies for non-experts to help them better understand how they can implement these in their own research and what to consider when planning an experiment. We also outline how these technologies are changing and how this change will influence human brain pathology in the future.

Funding statement

S.J. is funded by the European Union, Horizon 2020, Marie-Sklodowska Curie Actions EC no. 789492. A.W. is funded by the UK Multiple Sclerosis Society, Medical Research Council, Human Cell Atlas, F. Hoffmann-La Roche.

What have advances in transcriptomic technologies taught us about human white matter pathologies?

Sarah Jäkel^{1,*}, Anna Williams¹

¹ Centre for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh

* Correspondence:

Sarah Jäkel

sarah.jaekel@ed.ac.uk

Keywords: single cell transcriptomics, single nuclei transcriptomics, human neuropathology, white matter, Multiple Sclerosis, RNA-sequencing, “omics” approaches.

1 Abstract

For a long time, post-mortem analysis of human brain pathologies has been purely descriptive, limiting insight into the pathological mechanisms. However, starting in the early 2000's, next generation sequencing and the routine application of bulk RNA-sequencing and microarray technologies has revolutionized the usefulness of post-mortem human brain tissue. This has allowed many studies to provide novel mechanistic insights into certain brain pathologies, albeit at a still unsatisfying resolution, with masking of lowly expressed genes and of regulatory elements in different cell types. The recent rapid evolution of single cell technologies has now allowed researchers to shed light on human pathologies at a previously unreachable resolution revealing further insights into pathological mechanisms that will open the way for development of new strategies for therapies.

In this review, we will give an overview of the incremental information that single cell technologies have given us for human white matter pathologies, summarize which single cell technologies are available and speculate where these novel approaches may lead us for pathological assessment in the future.

2 Introduction

Classical approaches to study human white matter pathology

Modern neuropathology has its origins in the late 19th and early 20th century, when famous neurologists or psychologists such as Santiago Ramon y Cajal, Jean-Martin Charcot and Alois Alzheimer started to describe and illustrate the central nervous system (CNS) and its pathological changes. These early, but still accurate and detailed illustrations of the brain and individual cells, were all based on histological stains observed through a simple light microscope. It took many years before pathology could reach another level of detail with the common use of antibodies to develop marker-specific immunological stains that are still a state-of-the-art in modern research laboratories. Due to the combination with fluorescent labels and the development of better microscopes, this method has become a standard technique to study human pathology and it has helped us to gain a deep understanding of cellular and sub-cellular structures of the brain in health and disease.

Multiple Sclerosis (MS), a chronic inflammatory and demyelinating neurodegenerative disease of the central nervous system, is a good example of how this descriptive pathology is still used, but it equally

applies to other pathologies. The characteristic lesions in white matter (WM) tracts can be classified into active, chronic active, chronic inactive and remyelinated lesions – so called shadow plaques (Lassmann et al., 1998). This still highly used classification system is based on presence of demyelination and the distribution of infiltrating immune cells in and around the lesions and is carried out with simple histological staining on post-mortem human tissue. So far, there are only limited ways of detecting the different lesion stages during the lifetime of a patient using non-invasive imaging techniques (Bruck et al., 1997; Hemond and Bakshi, 2018). Specific magnetic resonance imaging sequences enables detection of chronic active lesions where acute inflammation is happening at the lesion rim (Absinta et al., 2018) and these are associated with disability and ongoing tissue damage (Absinta et al., 2019) aiding prognosis. These new imaging paradigms are exciting but we are still far from a full picture of MS lesions either by pathology or live imaging. Moreover, we still have limited knowledge about molecular or mechanistic changes in MS lesions which are key to understanding the disease.

With the development of new technologies in the 2000s, many labs started to use bulk RNA-sequencing (RNA-seq) or DNA-based microarrays to describe cellular and molecular changes in disease at the transcript level, to gain a deeper insight into functional pathological changes. This was the beginning of a revolution in pathology, helping define molecular markers of disease and raising new hypotheses for disease pathogenesis, to be tested experimentally. This revolution continues with new methods to identify transcripts from single cells or nuclei, and to identify these transcripts spatially on tissue. Here, we describe this revolution, and how this is evolving and will impact our understanding of human WM pathology. Although these techniques are applicable to a wide range of human WM CNS pathologies, this review will mostly use MS as an exemplar and only touch on other diseases where relevant.

3 Modern approaches to study WM pathologies

3.1 What have we learnt from whole transcriptomic approaches?

Bulk RNA-seq is a method to detect the entirety of the transcriptome within a sample of interest, which can either be a whole piece of tissue or sorted cells from a tissue. This can be done in an unbiased way where RNA is isolated, fragments transcribed into cDNA, which are further linked with specific adapters making them compatible with next generation sequencing (NGS), which is then bioinformatically analyzed (Fig. 1A). Alternatively, in a more biased way, isolated RNA is loaded onto specific microarray chips containing probes for only predefined gene transcripts. Commercial microarrays contain a large numbers of probes for the most important gene transcripts spread over the whole genome so that it can still be relatively unbiased. However, early experiments also included home-made arrays with lower numbers of genes.

The hallmark of WM MS pathology are the clearly distinguishable focal demyelinated lesions where myelin is lost. Therefore, due to its ease of detection and separation from the surrounding normal appearing white matter (NAWM), many groups have performed bulk transcriptome studies on MS tissue comparing these. In addition, probably in part due to its easier accessibility at least in life, many have been performed on body fluids such as blood or cerebrospinal fluid (CSF) but some also used whole brain or spinal cord tissue samples. Several review articles have already summarized these comparisons and discussed the technical challenges (Comabella and Martin, 2007; Kinter et al., 2008; Dutta and Trapp, 2012). In summary (Fig. 4), the major findings are that all analyzed tissue sources express high numbers of inflammatory gene transcripts, although the inflammatory pathways differ. In addition, it became clear that NAWM is not equal to control WM, suggesting that MS is a more global disease than previously thought. Many other findings of transcript differences across these

studies were unique to a specific gene transcript in one study rather than having common ground between studies, providing interesting candidates to be investigated. Most surprisingly and against the common concept in MS that oligodendrocytes are the primary target of attack, it has been suggested that surviving oligodendrocytes around demyelinating lesions in the NAWM are induced by hypoxia to be neuroprotective and anti-inflammatory and are thus more actively involved in disease and perhaps limiting it (Graumann et al., 2003; Zeis et al., 2008). Very recently, heparan sulphate production by mature oligodendrocytes around demyelinating lesions has been shown to be one of the mechanisms in limiting demyelinating lesions (Macchi et al., 2020). Lindberg et al. (2004) came to similar conclusions regarding the NAWM and additionally pointed out that the immune response activation is different in the different compartments with a more cellular response in NAWM and a humoral response in lesions. Looking a bit closer into differences between demyelinated lesions, Tajouri et al. (2003) found that although both acute and chronic lesions share the majority of markers that are changed in MS in comparison to control, the fold change of those gene transcripts is however quite different. More recent publications have used bulk RNA-seq on MS tissue in a more complex way to explore either transcriptomic changes of microglia in the initial phase of MS (van der Poel et al., 2019) or transcriptomic changes in an hormonal context of the hypothalamus-pituitary-adrenaline (HPA)-axis (Melief et al., 2019). The first study reported an increase in transcripts related to lipid metabolism in microglia sorted from NAWM that is similar to those found in active demyelinated lesions, however, whilst maintaining their homeostatic functions. The latter study found that gene expression networks in MS tissue correlate with the activity of the HPA axis and/or disease severity, showing that gene expression in a pathological context is not only regulated by the pathology itself, but also depends on other environmental factors. Thus, careful consideration of the experimental design and the case selection must be part of planning such an experiment.

Bulk transcriptomic approaches have brought several advantages to the field, but as ever with evolving technology, also some challenges. In contrast to immunohistochemistry (IHC) or quantitative PCR (qPCR) studies of candidate genes, it is unbiased, or relatively unbiased (with microarrays) allowing detection of new mechanisms rather than only digging deeper into already known ones. It is also not dependent on good primers/antibodies or experimenter choice. Long interfering non-coding RNAs are a good example of this, as most of their roles are relatively understudied and one specific RNA was found to play an important region-specific role in a study on Multiple System Atrophy (MSA), another human WM neuropathology, suggesting regional differences of this RNA to control brain function (Mills et al., 2015). Another advantage, at least in theory, is that studies that are performed by different groups in different tissues should be easy to compare, as all capture RNA in an unbiased way. However, disadvantages are plentiful, limiting comparisons as early studies (at least) used low numbers of individuals as input and findings might thus not be representative for a larger MS cohort. Comparisons chosen have varied and have included: (1) Lesions versus NAWM (Whitney et al., 1999; Whitney et al., 2001; Tajouri et al., 2003), (2) Lesions/NAWM versus Controls (Graumann et al., 2003; Lindberg et al., 2004; Zeis et al., 2008; Zeis et al., 2018), and (3) different lesions and/or different regions of lesions (Lock et al., 2002; Mycko et al., 2003; Hendrickx et al., 2017). Furthermore, MS lesions can occur in all WM regions and transcriptional profiling may be different when the lesions from the different studies come from different regions, for example from cerebellar WM and frontal subcortical WM. Many of these studies used non-standardized RNA isolation methods, different types of microarrays (commercial and homemade) with different probe sets (quantity and type) and also different sensitivities for lowly abundant genes, which may explain why different studies found so many different results. Highly abundant genes may mask more subtle effects, and in MS, this often leads to the discovery that MS lesions are associated with demyelination and inflammation (Kinter et al., 2008) – not quite a surprise for an inflammatory demyelinating disease.

A further disadvantage is that bulk transcriptomic studies detect gene expression irrespective of their cellular source within the tissue, so that a signal may be lost if one gene transcript is significantly upregulated in one cell type, but downregulated in another. This becomes especially important when studying a tissue with little cellular heterogeneity, as bulk approaches are generally able to detect a shift in cell type proportions (e.g. more inflammatory cells in MS lesions), but are less good in detecting changes within similar cells sharing the majority of transcripts.

3.2 How can complementary bulk approaches help address WM pathologies?

Other technologies, such as proteomics and metabolomics may also illuminate human pathologies (Fig. 1B, C). They are either suitable to help validate hypotheses generated by transcriptomics or to generate new hypotheses themselves. Proteomic approaches using different methods of mass spectrometry have been widely used (as summarized in (Farias et al., 2014;Farias and Santos, 2015)). Numerous studies have been performed on human blood and CSF samples, which are easier to obtain, and may allow the development of new disease biomarkers in living patients (Del Boccio et al., 2016) as well as elucidating potential mechanisms of pathogenesis. The scarcity of reliable blood or CSF biomarkers for MS has been quite sobering to date, which might also be due to the technical challenges of highly abundant proteins (e.g. albumin) in the samples that mask smaller changes. Few proteomic studies so far have been performed on human brain tissue itself, (Han et al., 2008;Broadwater et al., 2011;Ly et al., 2011) perhaps as a full proteomic overview of isolated brain tissue is technically challenging. This is due to the high abundance of proteins that cannot be captured by current technologies, mainly because of their dynamic range and the complexity, a reason why further subsampling of the tissue of interest might be helpful (Werner and Jahn, 2010). One study focussed on mitochondria in grey matter (GM), which suggested a dysfunction in the mitochondrial respiratory chain in MS (Broadwater et al., 2011). In line with the findings of bulk transcriptomics data, proteins involved in inflammation and demyelination were upregulated in MS, but in order to find new disease mechanisms that can be targeted for therapies, more specific and sensitive techniques are needed. However, proteomics have been elaborately applied in mouse models of MS and the results from these studies may be worth trying to validate in humans.

Metabolomics is a relatively newly termed “omics” approach to systemically study metabolites in a sample, and the first metabolomics studies in MS were performed in the 1990s (Lynch et al., 1993). This is useful as metabolites are usually the end product of a biological process allowing us to draw conclusions about function. Despite the novelty of this approach, it has already found a wide usage in MS and in its animal models, to try to identify biomarkers in body fluids like CSF, blood and urine. With this, it might also be possible to observe metabolites in different patients and respond to their individual needs by different drugs, which would be a first step to personalised precision medicine (Bhargava and Calabresi, 2016;Del Boccio et al., 2016).

Techniques to study brain WM in bulk have greatly shaped understanding of WM diseases, but we now have the technology to examine pathological changes at a single cell level, gaining even deeper and new insights into these diseases.

3.3 How do single cell transcriptomic techniques work?

Single cell RNA sequencing (scRNA-seq) is a novel technology using the same principle of capturing and sequencing mRNAs in bulk approaches within a tissue, however with the improvement that individual mRNAs can be associated with each cell of origin. This is particularly important for brain pathologies, where not all cell types are equally affected, for example in MS, where oligodendroglia

are primarily lost. Although scRNA-seq is a relatively young technology – the first paper was published in 2009 (Tang et al., 2009) - many different commercial techniques are already on the market and new ones are emerging at a rapid speed (Svensson et al., 2018;Chen et al., 2019), possibly faster than the publication of this review. Whilst all of them aim to give a snapshot of the transcriptome of individual cells, they are quite different in the technology achieving this. All of them have their advantages and disadvantages depending on the specific scientific question to be answered, so choosing the right technique is an important step in the experimental design. For this, we should consider the number of cells available, the capture efficiency, transcriptome coverage and cost per cell. Several reviews have summarized and compared single cell RNA-seq technologies (Haque et al., 2017;Picelli, 2017;Svensson et al., 2018;Chen et al., 2019). Despite the high number of technologies, from an experimental point of view, there are two approaches: studying a high number of cells at a lower resolution (up to tens of thousands of cells) or studying a low number of cells (generally <1000 cells) at a higher resolution.

The first approach generally uses droplet-based technologies (Macosko et al., 2015;Zheng et al., 2017), whilst the second approach mainly uses well- or device-based technologies (Fig. 2A,B) to capture single cells (Picelli et al., 2014;Hagemann-Jensen et al., 2020). Droplet-based methods use unique molecular identifiers (UMIs) and/or barcodes to label individual cells and mRNAs during the initial steps, so that the library preparation can be performed in bulk, rather than creating individual libraries in wells. As the droplet-based methods are aimed for high throughput, the costs per cell are much cheaper in comparison to well-based technologies. Also with this barcoding approach, copy numbers of mRNAs within a cell can at least in theory directly be measured, without the need of using additional standards such as External RNA Control Consortium (ERCC) spike-ins (Baker et al., 2005). In order to keep the sequencing costs at a realistic level, usually only the 3' or the 5' ends of the mRNA are amplified and sequenced, which only allows information of whether a gene is expressed or not, with a limited ability to examine splicing variants or SNPs. Conversely, with well- or device-based approaches, it allows study of splice variants of genes, but the cost per cell is higher.

Sometimes, a combination of both techniques might be useful. Using unbiased droplet-based techniques to look at the entirety of cells in a tissue of interest helps to get an overview of all cells, including rare cell populations, and to find appropriate markers for these. This is especially useful in understudied tissues such as the human brain, as established markers for rodent cells are not always appropriate in humans. Cell populations of further interest, including rare populations or subpopulations can then be studied at a deeper resolution using a full-length sequencing approach, after isolation or enrichment using the previously identified markers.

Currently, scRNA-seq experiments are cutting-edge and popular, generating much data and new hypotheses about the heterogeneity of cell function in all tissues with high impact publications. However, it is essential to validate these data and to keep the research question in mind, as sometimes a more classical approach will lead to an answer quicker, in an easier and cheaper way. Although bulk approaches seem to be outdated at the moment, these technologies have also improved and are still important tools in studying human pathologies.

3.4 What are the challenges and drawbacks of performing human single cell RNA-seq?

All of these single cell technologies were originally developed for cultured cells or rodent tissue, whilst their application to human tissue has only started to boom in recent years. Besides ethical constraints and the limited availability of human tissue (control equally as pathological tissue), there are more technical challenges that delayed the revolution in this field. Single cell technologies were developed for viable single cell suspensions, which is often not possible in WM pathologies, where most tissue is obtained post-mortem and not during biopsies. Hence, cell viability and tissue quality is often already below the accepted threshold to perform the experiments once the tissue arrives in the hands of the

researcher. By this time, surviving cells may be highly selected and their transcriptome likely to have changed dramatically, with degraded RNA resulting in bad data quality and lower biological meaning. Moreover, in order to reduce confounding factors, all samples should be run ideally together or at least in as small a number of batches as possible (Hicks et al., 2017), which is impossible when using fresh biopsy or autopsy material, as individual tissue samples are sometimes only available months apart. For these reasons, most research so far in human brain have used single nuclei (sn) RNAseq using the same technologies from archived and frozen tissue samples instead of fresh viable cells. On comparing cells versus nuclei, there is now the general consensus that although nuclei generally yield a lower number of reads, they can add useful information on the biology. This tissue source may even protect from immediate changes in the transcriptome resulting from cell stress during cell isolation and the proportional representation of the *in-vivo* situation may be more preserved, as during a live isolation, vulnerable cells are more likely to die resulting in their underrepresentation (Bakken et al., 2018; Wu et al., 2019). However, a new study suggested that using nuclei is not always a good alternative, as only highly abundant transcripts are detected and the more subtle changes related to the activation state of human microglia could not be distinguished (Thrupp et al., 2020). To get a clear picture of the advantages and disadvantages of using nuclei or cells, more comparative work using the same tissues, experimental setups and sequencing depth will be helpful. However, given the high number of publications, it is already clear that snRNA-seq is an important tool to resolve biological questions, especially for human pathologies when no other tissue source is available.

More generally, once the decision has been made to use cells or nuclei, other challenges arise. Although at first sight, plentiful rich data is a clear advantage, it can also lead to data overload, that nobody knows what to do with. Especially with droplet-based technologies, individual sc/snRNA-seq experiments generate so many data points that research groups may only process a small part of it: for example, the experimental design might include all unselected nuclei, however, only a certain cell-type may be analysed. Here is where open access sharing of these data is essential, allowing other groups to use these data to address their own research questions and save a lot of time. This also allows for some mitigation of expense, as the rapid development of these technologies comes at high cost. Although these techniques are becoming cheaper, the costs of commercial kits are still high and the cost per cell must be considered in the experimental plan. Homemade technologies are inevitably cheaper, but require knowledge and time to set up and may not be as robust and comparable between research labs as commercial ones. The costs for the sequencing should not be forgotten, which often equal the cost of the cell capture and cDNA library preparation. The depth of the experimental analysis obtained depends on the depth of sequencing.

A major limitation of sc/snRNA-seq is the the number of transcripts that can be detected within a cell. Although the captured transcripts are often treated as representing the entirety of the transcriptome, in reality only about 5-20% of the transcripts are captured depending on the method, leaving about 80% of the biology undiscovered (Islam et al., 2014; Ding et al., 2020). These missing transcripts are usually ones with a low abundance that may represent more subtle changes between cell states. A recent advance is the development of a full-length sequencing method that reaches a significantly deeper transcriptome coverage per cell and thus results in a clearer separation of clusters (Hagemann-Jensen et al., 2020), but unfortunately, this method is not yet suitable for high throughput. Another limitation of these technologies comes from the way in which RNA is captured. Most methods use oligos to capture polyadenylated mRNA only and especially droplet-based methods, additionally only use 3' amplification. Few technologies have been developed to amplify the 5' end of the RNA, however the libraries are also prepared with the polyA-tail, still only accounting for the same type of RNA (Svensson et al., 2018; Chen et al., 2019). Other forms of biologically interesting RNAs, such as many microRNAs are not identifiable using this capture method and detection of splicing variants of genes is more limited (unless using full-length sequencing).

Once the sequencing data are generated, data storage is another often unconsidered problem. As datasets become bigger, in terms of sample number, cell number and sequencing depth, the output data files become bigger and too large to be stored on a standard computer, instead requiring big data servers or cloud storage, which come at a further cost. Data handling capacity challenges go hand in hand with increasing data size and depth, and analysis of these datasets generally requires a high-end workstation or, better, access to a computational cluster with the respective expertise. Associated with the fast development of scRNA-seq technologies, there is a large expansion in the available tools for data analysis, which are evolving all of the time and are generally open source and therefore free. This can give a bewildering variety of options of how to analyse the dataset. The challenge here is to find the right tool that is suitable for the data of interest, as not all available tools are. Helpful comparisons have emerged, for example in an overview of 45 current tools to calculate pseudotime trajectories (Saelens et al., 2019), as not all of them are equally suited for every dataset. Another example would be the availability of different clustering methods, with Seurat (Satija et al., 2015), Monocle (Trapnell et al., 2014) and Conos (Barkas et al., 2019) as highly used examples. Each of them uses a different algorithm and clustering approach, as outlined in (Duò et al., 2018) and might thus result in different final clusters of which all may be valid. These are only examples, but every step in the experimental and the analysis part has many options. One study outlined this problem and showed that using only a minimum of options in different steps and combining it in a different way already results in ~3000 different pipelines for analysis (Vieth et al., 2019). This field is as experimental as wet lab work, and it may be useful to use several analysis tools purporting to do the same thing on one dataset, in order to determine how robust the analysis is. However, ultimately, the only way to discover if the analysis is correct is to validate the results using other methods.

3.5 What have we learnt about WM pathologies using single cell/nuclei transcriptomic approaches?

Pioneering scRNA-seq analysis in rodent brain tissue clearly showed detection of all brain cells that were distinguishable by specific markers (Zeisel et al., 2015). Of interest to MS, a key study in mouse oligodendrocytes (Marques et al., 2016) first used scRNA-seq to report their heterogeneity suggesting different inherent functions of oligodendrocytes not only between the brain and the spinal cord, but even in the same region of the brain. The first studies using snRNA-seq on normal human brain tissue were proof of principle that this method was suitable in such a tissue and that there is cellular and regional heterogeneity (Habib et al., 2017; Lake et al., 2018) and were the starting point of many following studies. Not surprisingly, it did not take long before this technology was used to study brain pathologies including MS (Fig. 4).

With this hitherto unreachable resolution, cellular heterogeneity in MS tissue was demonstrated in oligodendrocytes, neurons, microglia and astrocytes (Jakel et al., 2019; Masuda et al., 2019; Schirmer et al., 2019; Wheeler et al., 2020) with disease-specific cell types or different heterogeneous states present in different proportions in MS compared to controls. In their study, Jakel et al. (2019) found heterogeneous oligodendroglial states in non-pathological brain tissue and contrary to the current idea that all oligodendrocytes in MS lesions are equally vulnerable, reported that some of these states were over- and some underrepresented. Although the functional role of this cellular heterogeneity is not yet clear, this skew in the proportions of different oligodendrocyte states seen in MS was present in both NAWM and in MS lesions, again adding to the evidence that NAWM is indeed not normal, as previously shown for microglia (van der Poel et al., 2019). Furthermore, these data were able to identify a small population of previously unknown oligodendroglia with immunological functions (Falcão et al., 2018; Jakel et al., 2019) which may influence disease pathogenesis as it suggests that oligodendrocytes may be an active player in the disease as well as a vulnerable target. This is of

importance, as therapeutic approaches simply aiming to increase differentiation of oligodendrocytes to improve remyelination may need to be reconsidered, as replacing the ‘correct’ type may be preferred. Another study using a similar approach to address the cellular composition of MS lesions found specific signatures for stressed oligodendrocytes, reactive astrocytes and activated microglia, especially at the rim of demyelinated lesions. As this study also included cortical grey matter tissue, the authors reported a selective loss of CUX2-expressing upper layer excitatory projection neurons in the grey matter both in demyelinated and partially remyelinated lesions (Schirmer et al., 2019). In line with the previous study, they also found that some stressed oligodendrocytes seem to be capable of antigen presentation. This again confirms that damage does not affect all cells equally and that there is still a large gap of knowledge about disease mechanisms in MS. These studies are mostly descriptive, but a recent study in zebrafish has demonstrated that two distinct subgroups of oligodendrocyte precursor cells (OPCs) identified by scRNA-seq are confirmed to be functionally distinct with one primarily making networks and the other primarily differentiating into oligodendrocytes to make myelin (Marisca et al., 2020). Although this study was performed on normal zebrafish, this may also be important as if this is similar in humans, it may again force us to rethink our therapeutic remyelination strategies in MS, aiming to stimulate differentiating OPCs selectively. With a focus on microglia, Masuda et al. (2019) described microglial heterogeneity for the first time in non-pathological human brain and additionally found clusters of disease-related microglia in MS patients that were similar to rodent animal models of MS, but with a high inter-personal variability. A very recent study has directed its focus on astrocytes in MS showing that astrocytes in mice and human are also heterogeneous. The authors found a clear MS-associated astrocyte cluster actively promoting CNS inflammation by the regulation of gene expression (Wheeler et al., 2020).

These technologies have also reached other human brain pathologies such as Alzheimer’s disease (AD) (Grubman et al., 2019; Mathys et al., 2019; Zhou et al., 2020), Huntington’s disease (Al-Dalahmah et al., 2020) and other psychiatric disorders (Renthal et al., 2018; Velmeshev et al., 2019; Nagy et al., 2020). Although AD is usually considered a neuronal disease mostly of the GM, it has been surprisingly found that oligodendrocytes in the WM do show a significant transcriptional change in the disease apparently adapting their metabolism to neuronal degeneration (Mathys et al., 2019; Zhou et al., 2020). OPCs also seem involved, as in AD, OPCs repress apolipoprotein E (APOE), which is a genetic risk factor for this disease, strengthening the hypothesis that oligodendroglia actively contribute to pathogenesis (Grubman et al., 2019). This study used the known AD risk genes to study how these contribute to disease in a cell-specific manner, as a relevant strategy to focus the analysis of the wealth of data. Another recent study found that besides neurons, OPCs are majorly disturbed in major depressive disorder and this seemed to be coupled with their interaction with neurons rather than their ability to differentiate and myelinate (Nagy et al., 2020), which demonstrated that using this technology is important to disentangle the functions of subsets of cells. Most importantly, these new studies have started to shed new light on neurodegenerative and psychiatric diseases, moving away from a neurocentric view of these diseases with new recognition of the importance of glial cells in their pathogenesis - a shift in the research landscape.

3.6 What other techniques can we use to complement the sc/snRNAseq approach?

RNA-seq at a single cell/nuclei level is only the start, with the fast development of other single cell resolution technologies, including epigenetic methods. Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) has already long been used to assess the bulk chromatin accessibility and the chromatin signature of cellular DNA (Buenrostro et al., 2013) including the human brain in health and disease (Corces et al., 2017; Bryois et al., 2018; Fullard et al., 2018), but can now also be done at the single cell/nuclear level (Fig. 2C). This adds information about transcriptional regulation

of different cell types and has already widely been used on rodent (Preissl et al., 2018; Sinnamon et al., 2019), but also on human brain tissue (Zhong et al., 2020). A very recent study used this method to identify new single nucleotide polymorphisms (SNPs) with a more functional annotation than classically found with GWAS and found new risk-factors for Parkinson's and Alzheimer's disease (Corces et al., 2020). Bioinformatics tools are emerging to integrate scRNA-seq with scATAC-seq data in order to get a deeper understanding of the transcriptional and genomic landscape within one individual cell. Further explorations of the epigenomic landscape at a single cell level include DNA methylation profiling to detect methylation marks identifying regulatory programmes in different cell populations (summarized in (Fiers et al., 2018)). It is already possible to detect epigenetic marks and gene expression in the same cell, not only bioinformatically but also experimentally, as shown with the sc-GEM (single cell analysis of genotype, expression and methylation) assay on cultured human fibroblasts (Cheow et al., 2016) and its use on human tissue would be another highly valuable method to understand its pathology.

Clearly, single cell DNA/RNA changes can imply function but protein detection adds a further level of information to determine a cell's behaviour. Single cell technologies have also entered the protein field with Cytometry by time of flight (CyTOF), although this is not yet unbiased but requires a selection of markers of interest. This method uses metal-labelled antibodies to detect cellular antigens that are then analysed by mass cytometry. This approach is similar to classical Fluorescence-activated cell sorting (FACS), but with a broader separation of metals which overcomes the limit of the overlap of fluorophores and allows the use of around 40 antibodies together (up to 100 when considering isotopes as well). With a bioinformatics analysis approach, high numbers of single cells can be thoroughly profiled. This approach has been used to characterize a change in the populations of peripheral immune cells of MS patients (Bottcher et al., 2019a) as well as to characterize multiple different region-dependent populations of microglia in human brain that are clearly distinguishable from peripheral cells (Bottcher et al., 2019b). CyTOF can also directly be applied to histological tissue sections – called imaging mass cytometry – and can be used to profile individual cells whilst maintaining the spatial information. Although still a fledgling technique at the spatial level, this has already successfully been applied in MS brain tissue to characterize astrocytes and peripheral cells in MS lesions (Park et al., 2019) and to characterize the immune cell landscape within different lesions from an individual MS patient (Ramaglia et al., 2019).

For a disease such as MS, spatial information is clearly very important, due to the focal nature of demyelinated lesions, but there may also be pathological changes in more restricted areas in other neurodegenerative pathologies as well, e.g. in AD. Although not yet at a single cell resolution, spatial transcriptomics technologies aim to capture the whole transcriptome of each of very small areas of a tissue section in an unbiased way in combination with histological analysis (Stahl et al., 2016). Using the same principle of capturing and barcoding mRNA as droplet-based methods, this technology allows location of the origin of an individual mRNA to a defined spot on a predefined grid on which the tissue has been placed, thus maintaining the spatial information. This technology is already being used on human tissue (Maynard et al., 2020), and with an earlier version in ALS (Gregory et al., 2020). With the clear advantage of capturing the transcriptome at a high resolution whilst maintaining spatial information, spatial transcriptomics technologies are clearly at the forefront of development and may in the future be more widely used than current sc/snRNA-seq technologies. They are either based on sequencing the transcripts *in situ* after having been barcoded (Ke et al., 2013; Lee et al., 2014; Wang et al., 2018; Gregory et al., 2020; Lundin et al., 2020; Maynard et al., 2020), or use highly multiplexed single molecular fluorescent *in situ* hybridisation probes detectable using confocal microscopy (Lubeck et al., 2014; Shah et al., 2016). The current limitation of sequencing-based methods is the low detection of transcripts. Multiplexed *in situ* methods on the other hand are restricted by the number of probes (hundreds to thousands) due to the limited availability of fluorophores and optical resolution of individual molecules, making them less suitable for an unbiased discovery-driven research approach.

However, recent developments have combined the methods, using sequential hybridisation with *in situ* sequencing to theoretically cover the whole transcriptome with only few fluorophores (Shah et al., 2016; Eng et al., 2019). As a result, a higher number of transcripts per cell can be detected. Although these methods have not yet been implemented on human brain tissue, which will be challenging due to its high autofluorescence, this high resolution of individual mRNAs will not only allow the localization of cells within a tissue, but also will allow study of the subcellular localization of mRNAs, clear advantages in comparison to scRNA-seq methods. Unfortunately, these methods do only work well on thin tissue sections, limiting the information we gain from a three-dimensional point of view. Sequencing-driven spatial methods in particular are still expensive and are thus tend to be performed on small tissue pieces with few sections from an individual, which may introduce some bias to the biological findings.

Validation of results, preferably on a separate cohort of tissue, is essential by classical immunohistochemistry/fluorescence and *in situ* hybridisation, and/or these burgeoning multiplexing technologies, mentioned above. These have allowed spatially detection of 100 different transcripts by *in situ* sequencing (Lundin et al., 2020) or around 100 proteins and 1000 genes using oligonucleotide labelling in a tissue section (Geiss et al., 2008; Kulkarni, 2011). Although imaging mass cytometry is usually used to characterize novel cell populations, it can clearly serve as a validation method for transcriptomic data as well. These require analysis tools to distinguish signals in different cells, but appear very useful and are likely to become standard to address human pathologies in the future.

3.7 What does the future hold?

The outputs of all of these technologies applied to human white matter pathologies are still no more than descriptive pathology – although on a much deeper level than was ever possible before and at least implying function. This work however, is just the start of a new era of single cell resolution techniques that will revolutionize human pathology and will most likely become a standard technology for pathological assessment. The richness of these data will allow us to take the next step, which is to address more functional changes to gain a deeper understanding of the diseases. For example, snRNA-seq will allow us to study transcriptomic changes in a high numbers of cells in many different types of MS lesions which then may allow us to reclassify them on a functional level, namely their regenerative potential rather than using the classical degenerative description. Moreover, these data may allow us to determine lesion markers that can be used for PET-imaging and will thus be an invaluable tool for disease diagnosis, prognosis and response to therapies. Furthermore, as most of the data are gained in a similar way and deposited with its metadata on open-source databases, it is then easier to compare many brain regions (such as WM and GM, or brain and spinal cord) or diseases with each other, to gain a much clearer picture of the cellular architecture of our brain. The Human Cell Atlas is a collaborative effort to exactly achieve this aim (<https://www.humancellatlas.org/>) not only for the brain, but for the entire human body.

So far, most of these technologies are used individually by different groups but in the future, complimentary but different technologies will be used in the same experimental setup, and their outputs integrated, as recently shown from the Allen Brain Institute (Bakken et al., 2020). Maybe in ten years from now it will be possible to look at the transcriptome, the epigenome, the proteome and the metabolome on a single cell level from the same tissue source at once, as suggested in Fig. 3. Attempts to achieve this have already been made in recent preprint manuscripts where the authors were able to simultaneously study either proteins and mRNA (Vistain et al., 2020) or chromatin accessibility and gene expression (Ma et al., 2020) in single cells. This will allow us to look at the same data from many different perspectives to gain a deeper understanding of individual cells in health and disease and further explore pathological mechanism. The options here seem endless with money as the only limit!

4 Concluding remarks

Analysis and understanding of human WM pathologies has come a long way from being purely descriptive histological analysis to gaining cell type-specific information at a single-cell resolution (Fig. 4). This development goes hand in hand with the development of novel technologies, although their use in human tissue is inevitably more challenging than in animal models. We can now sequence the RNA of a cell, examine the state of the chromatin and it is likely that current proteomic tools will become more sensitive as well, which will allow us to explore the proteome of individual cells. Although all of these technologies have developed separately, we will need to link them together in order to see the full picture in the future. This will allow us to gain a deeper insight into human pathologies and will become important tools not only for basic science, but will also revolutionize diagnostics and may pave the way for developing new therapies. However, even though these technologies are developing at an exciting and rapid speed, it is important to retain a clear focus on the research question to be answered, to avoid distraction by an ocean of data and high costs, and to ensure that we advance biology.

5 Author Contributions

S.J. and A.W. wrote and edited the manuscript. S.J. also designed and prepared the figures.

6 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

7 Acknowledgments

All figures created with [BioRender.com](https://www.biorender.com).

8 Funding

S.J. is funded by the European Union, Horizon 2020, Marie-Skłodowska Curie Actions EC no. 789492. A.W. is funded by the UK Multiple Sclerosis Society, Medical Research Council, Human Cell Atlas, F. Hoffmann-La Roche.

9 References

- Absinta, M., Sati, P., Fechner, A., Schindler, M.K., Nair, G., and Reich, D.S. (2018). Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI. *AJNR. American journal of neuroradiology* 39, 1233-1238.
- Absinta, M., Sati, P., Masuzzo, F., Nair, G., Sethi, V., Kolb, H., Ohayon, J., Wu, T., Cortese, I.C.M., and Reich, D.S. (2019). Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. *JAMA Neurol.*
- Al-Dalahmah, O., Sosunov, A.A., Shaik, A., Ofori, K., Liu, Y., Vonsattel, J.P., Adorjan, I., Menon, V., and Goldman, J.E. (2020). Single-nucleus RNA-seq identifies Huntington disease astrocyte states. *Acta Neuropathologica Communications* 8, 19.
- Baker, S.C., Bauer, S.R., Beyer, R.P., Brenton, J.D., Bromley, B., Burrill, J., Causton, H., Conley, M.P., Elespuru, R., Fero, M., Foy, C., Fuscoe, J., Gao, X., Gerhold, D.L., Gilles, P., Goodsaid, F., Guo, X., Hackett, J., Hockett, R.D., Ikonomi, P., Irizarry, R.A., Kawasaki, E.S.,

- 494 Kaysser-Kranich, T., Kerr, K., Kiser, G., Koch, W.H., Lee, K.Y., Liu, C., Liu, Z.L., Lucas,
495 A., Manohar, C.F., Miyada, G., Modrusan, Z., Parkes, H., Puri, R.K., Reid, L., Ryder, T.B.,
496 Salit, M., Samaha, R.R., Scherf, U., Sendera, T.J., Setterquist, R.A., Shi, L., Shippy, R.,
497 Soriano, J.V., Wagar, E.A., Warrington, J.A., Williams, M., Wilmer, F., Wilson, M., Wolber,
498 P.K., Wu, X., Zadro, R., and The External, R.N.a.C.C. (2005). The External RNA Controls
499 Consortium: a progress report. *Nature Methods* 2, 731-734.
- 500 Bakken, T.E., Hodge, R.D., Miller, J.A., Yao, Z., Nguyen, T.N., Aeversmann, B., Barkan, E.,
501 Bertagnolli, D., Casper, T., Dee, N., Garren, E., Goldy, J., Graybuck, L.T., Kroll, M., Lasken,
502 R.S., Lathia, K., Parry, S., Rimorin, C., Scheuermann, R.H., Schork, N.J., Shehata, S.I., Tieu,
503 M., Phillips, J.W., Bernard, A., Smith, K.A., Zeng, H., Lein, E.S., and Tasic, B. (2018).
504 Single-nucleus and single-cell transcriptomes compared in matched cortical cell types. *PLoS*
505 *One* 13, e0209648.
- 506 Bakken, T.E., Jorstad, N.L., Hu, Q., Lake, B.B., Tian, W., Kalmbach, B.E., Crow, M., Hodge, R.D.,
507 Krienen, F.M., Sorensen, S.A., Eggermont, J., Yao, Z., Aeversmann, B.D., Aldridge, A.I.,
508 Bartlett, A., Bertagnolli, D., Casper, T., Castanon, R.G., Crichton, K., Daigle, T.L., Dalley,
509 R., Dee, N., Dembrow, N., Diep, D., Ding, S.-L., Dong, W., Fang, R., Fischer, S., Goldman,
510 M., Goldy, J., Graybuck, L.T., Herb, B.R., Hou, X., Kancharla, J., Kroll, M., Lathia, K., Lew,
511 B.V., Li, Y.E., Liu, C.S., Liu, H., Mahurkar, A., Mcmillen, D., Miller, J.A., Moussa, M.,
512 Nery, J.R., Orvis, J., Owen, S., Palmer, C.R., Pham, T., Plongthongkum, N., Poirion, O.,
513 Reed, N.M., Rimorin, C., Rivkin, A., Romanow, W.J., Sedeño-Cortés, A.E., Siletti, K.,
514 Somasundaram, S., Sulc, J., Tieu, M., Torkelson, A., Tung, H., Wang, X., Xie, F., Yanny,
515 A.M., Zhang, R., Ament, S.A., Bravo, H.C., Chun, J., Dobin, A., Gillis, J., Hertzano, R., Hof,
516 P.R., Höllt, T., Horwitz, G.D., Keene, C.D., Kharchenko, P.V., Ko, A.L., Lelieveldt, B.P.,
517 Luo, C., Mukamel, E.A., Preissl, S., Regev, A., Ren, B., Scheuermann, R.H., Smith, K.,
518 Spain, W.J., White, O.R., Koch, C., Hawrylycz, M., Tasic, B., Macosko, E.Z., Mccarroll,
519 S.A., Ting, J.T., Zeng, H., Zhang, K., Feng, G., Ecker, J.R., Linnarsson, S., and Lein, E.S.
520 (2020). Evolution of cellular diversity in primary motor cortex of human, marmoset monkey,
521 and mouse. *bioRxiv*, 2020.2003.2031.016972.
- 522 Barkas, N., Petukhov, V., Nikolaeva, D., Lozinsky, Y., Demharter, S., Khodosevich, K., and
523 Kharchenko, P.V. (2019). Joint analysis of heterogeneous single-cell RNA-seq dataset
524 collections. *Nature Methods* 16, 695-698.
- 525 Bhargava, P., and Calabresi, P.A. (2016). Metabolomics in multiple sclerosis. *Mult Scler* 22, 451-
526 460.
- 527 Bottcher, C., Fernandez-Zapata, C., Schlickeiser, S., Kunkel, D., Schulz, A.R., Mei, H.E., Weidinger,
528 C., Giess, R.M., Asseier, S., Siegmund, B., Paul, F., Ruprecht, K., and Priller, J. (2019a).
529 Multi-parameter immune profiling of peripheral blood mononuclear cells by multiplexed
530 single-cell mass cytometry in patients with early multiple sclerosis. *Sci Rep* 9, 19471.
- 531 Bottcher, C., Schlickeiser, S., Sneeboer, M.a.M., Kunkel, D., Knop, A., Paza, E., Fidzinski, P.,
532 Kraus, L., Snijders, G.J.L., Kahn, R.S., Schulz, A.R., Mei, H.E., Hol, E.M., Siegmund, B.,
533 Glauben, R., Spruth, E.J., De Witte, L.D., and Priller, J. (2019b). Human microglia regional
534 heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. *Nat*
535 *Neurosci* 22, 78-90.
- 536 Broadwater, L., Pandit, A., Clements, R., Azzam, S., Vadnal, J., Sulak, M., Yong, V.W., Freeman,
537 E.J., Gregory, R.B., and McDonough, J. (2011). Analysis of the mitochondrial proteome in
538 multiple sclerosis cortex. *Biochim Biophys Acta* 1812, 630-641.

Running Title: Pathology at single cell resolution

- 539 Bruck, W., Bitsch, A., Kolenda, H., Bruck, Y., Stiefel, M., and Lassmann, H. (1997). Inflammatory
540 central nervous system demyelination: correlation of magnetic resonance imaging findings
541 with lesion pathology. *Ann Neurol* 42, 783-793.
- 542 Bryois, J., Garrett, M.E., Song, L., Safi, A., Giusti-Rodriguez, P., Johnson, G.D., Shieh, A.W., Buil,
543 A., Fullard, J.F., Roussos, P., Sklar, P., Akbarian, S., Haroutunian, V., Stockmeier, C.A.,
544 Wray, G.A., White, K.P., Liu, C., Reddy, T.E., Ashley-Koch, A., Sullivan, P.F., and
545 Crawford, G.E. (2018). Evaluation of chromatin accessibility in prefrontal cortex of
546 individuals with schizophrenia. *Nat Commun* 9, 3121.
- 547 Buenrostro, J.D., Giresi, P.G., Zaba, L.C., Chang, H.Y., and Greenleaf, W.J. (2013). Transposition of
548 native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding
549 proteins and nucleosome position. *Nature Methods* 10, 1213-1218.
- 550 Chen, G., Ning, B., and Shi, T. (2019). Single-Cell RNA-Seq Technologies and Related
551 Computational Data Analysis. *Front Genet* 10, 317.
- 552 Cheow, L.F., Courtois, E.T., Tan, Y., Viswanathan, R., Xing, Q., Tan, R.Z., Tan, D.S., Robson, P.,
553 Loh, Y.H., Quake, S.R., and Burkholder, W.F. (2016). Single-cell multimodal profiling
554 reveals cellular epigenetic heterogeneity. *Nat Methods* 13, 833-836.
- 555 Comabella, M., and Martin, R. (2007). Genomics in multiple sclerosis--current state and future
556 directions. *J Neuroimmunol* 187, 1-8.
- 557 Corces, M.R., Shcherbina, A., Kundu, S., Gloudemans, M.J., Frésard, L., Granja, J.M., Louie, B.H.,
558 Shams, S., Bagdatli, S.T., Mumbach, M.R., Liu, B., Montine, K.S., Greenleaf, W.J., Kundaje,
559 A., Montgomery, S.B., Chang, H.Y., and Montine, T.J. (2020). Single-cell epigenomic
560 identification of inherited risk loci in Alzheimer's and Parkinson's disease. *bioRxiv*,
561 2020.2001.2006.896159.
- 562 Corces, M.R., Trevino, A.E., Hamilton, E.G., Greenside, P.G., Sinnott-Armstrong, N.A., Vesuna, S.,
563 Satpathy, A.T., Rubin, A.J., Montine, K.S., Wu, B., Kathiria, A., Cho, S.W., Mumbach, M.R.,
564 Carter, A.C., Kasowski, M., Orloff, L.A., Risca, V.I., Kundaje, A., Khavari, P.A., Montine,
565 T.J., Greenleaf, W.J., and Chang, H.Y. (2017). An improved ATAC-seq protocol reduces
566 background and enables interrogation of frozen tissues. *Nature Methods* 14, 959-962.
- 567 Del Boccio, P., Rossi, C., Di Ioia, M., Cicalini, I., Sacchetta, P., and Pieragostino, D. (2016).
568 Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery
569 to personalized medicine. *Proteomics Clin Appl* 10, 470-484.
- 570 Ding, J., Adiconis, X., Simmons, S.K., Kowalczyk, M.S., Hession, C.C., Marjanovic, N.D., Hughes,
571 T.K., Wadsworth, M.H., Burks, T., Nguyen, L.T., Kwon, J.Y.H., Barak, B., Ge, W.,
572 Kedaigle, A.J., Carroll, S., Li, S., Hacohen, N., Rozenblatt-Rosen, O., Shalek, A.K., Villani,
573 A.C., Regev, A., and Levin, J.Z. (2020). Systematic comparison of single-cell and single-
574 nucleus RNA-sequencing methods. *Nat Biotechnol* 38, 737-746.
- 575 Duò, A., Robinson, M.D., and Soneson, C. (2018). A systematic performance evaluation of
576 clustering methods for single-cell RNA-seq data. *F1000Research* 7, 1141-1141.
- 577 Dutta, R., and Trapp, B.D. (2012). Gene expression profiling in multiple sclerosis brain. *Neurobiol*
578 *Dis* 45, 108-114.
- 579 Eng, C.L., Lawson, M., Zhu, Q., Dries, R., Koulana, N., Takei, Y., Yun, J., Cronin, C., Karp, C.,
580 Yuan, G.C., and Cai, L. (2019). Transcriptome-scale super-resolved imaging in tissues by
581 RNA seqFISH. *Nature* 568, 235-239.

- 582 Falcao, A.M., Van Bruggen, D., Marques, S., Meijer, M., Jakel, S., Agirre, E., Samudiyata, Floriddia,
583 E.M., Vanichkina, D.P., Ffrench-Constant, C., Williams, A., Guerreiro-Cacais, A.O., and
584 Castelo-Branco, G. (2018). Disease-specific oligodendrocyte lineage cells arise in multiple
585 sclerosis. *Nat Med* 24, 1837-1844.
- 586 Farias, A.S., Pradella, F., Schmitt, A., Santos, L.M., and Martins-De-Souza, D. (2014). Ten years of
587 proteomics in multiple sclerosis. *Proteomics* 14, 467-480.
- 588 Farias, A.S., and Santos, L.M. (2015). How can proteomics elucidate the complexity of multiple
589 sclerosis? *Proteomics Clin Appl* 9, 844-847.
- 590 Fiers, M., Minnoye, L., Aibar, S., Bravo Gonzalez-Blas, C., Kalender Atak, Z., and Aerts, S. (2018).
591 Mapping gene regulatory networks from single-cell omics data. *Brief Funct Genomics* 17,
592 246-254.
- 593 Fullard, J.F., Hauberg, M.E., Bendl, J., Egervari, G., Cîrnaru, M.D., Reach, S.M., Motl, J., Ehrlich,
594 M.E., Hurd, Y.L., and Roussos, P. (2018). An atlas of chromatin accessibility in the adult
595 human brain. *Genome Res* 28, 1243-1252.
- 596 Geiss, G.K., Bumgarner, R.E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D.L., Fell, H.P., Ferree,
597 S., George, R.D., Grogan, T., James, J.J., Maysuria, M., Mitton, J.D., Oliveri, P., Osborn,
598 J.L., Peng, T., Ratcliffe, A.L., Webster, P.J., Davidson, E.H., Hood, L., and Dimitrov, K.
599 (2008). Direct multiplexed measurement of gene expression with color-coded probe pairs.
600 *Nature Biotechnology* 26, 317-325.
- 601 Graumann, U., Reynolds, R., Steck, A.J., and Schaeren-Wiemers, N. (2003). Molecular changes in
602 normal appearing white matter in multiple sclerosis are characteristic of neuroprotective
603 mechanisms against hypoxic insult. *Brain Pathol* 13, 554-573.
- 604 Gregory, J.M., Mcdade, K., Livesey, M.R., Croy, I., Marion De Proce, S., Aitman, T., Chandran, S.,
605 and Smith, C. (2020). Spatial transcriptomics identifies spatially dysregulated expression of
606 GRM3 and USP47 in amyotrophic lateral sclerosis. *Neuropathol Appl Neurobiol*.
- 607 Grubman, A., Chew, G., Ouyang, J.F., Sun, G., Choo, X.Y., Mclean, C., Simmons, R.K., Buckberry,
608 S., Vargas-Landin, D.B., Poppe, D., Pflueger, J., Lister, R., Rackham, O.J.L., Petretto, E., and
609 Polo, J.M. (2019). A single-cell atlas of entorhinal cortex from individuals with Alzheimer's
610 disease reveals cell-type-specific gene expression regulation. *Nat Neurosci* 22, 2087-2097.
- 611 Habib, N., Avraham-Davidi, I., Basu, A., Burks, T., Shekhar, K., Hofree, M., Choudhury, S.R.,
612 Aguet, F., Gelfand, E., Ardlie, K., Weitz, D.A., Rozenblatt-Rosen, O., Zhang, F., and Regev,
613 A. (2017). Massively parallel single-nucleus RNA-seq with DroNc-seq. *Nat Methods* 14, 955-
614 958.
- 615 Hagemann-Jensen, M., Ziegenhain, C., Chen, P., Ramsköld, D., Hendriks, G.-J., Larsson, A.J.M.,
616 Faridani, O.R., and Sandberg, R. (2020). Single-cell RNA counting at allele and isoform
617 resolution using Smart-seq3. *Nature Biotechnology* 38, 708-714.
- 618 Han, M.H., Hwang, S.-I., Roy, D.B., Lundgren, D.H., Price, J.V., Ousman, S.S., Fernald, G.H.,
619 Gerlitz, B., Robinson, W.H., Baranzini, S.E., Grinnell, B.W., Raine, C.S., Sobel, R.A., Han,
620 D.K., and Steinman, L. (2008). Proteomic analysis of active multiple sclerosis lesions reveals
621 therapeutic targets. *Nature* 451, 1076-1081.
- 622 Haque, A., Engel, J., Teichmann, S.A., and Lonnberg, T. (2017). A practical guide to single-cell
623 RNA-sequencing for biomedical research and clinical applications. *Genome Med* 9, 75.

Running Title: Pathology at single cell resolution

- 624 Hemond, C.C., and Bakshi, R. (2018). Magnetic Resonance Imaging in Multiple Sclerosis. *Cold*
625 *Spring Harb Perspect Med* 8.
- 626 Hendrickx, D.a.E., Van Scheppingen, J., Van Der Poel, M., Bossers, K., Schuurman, K.G., Van
627 Eden, C.G., Hol, E.M., Hamann, J., and Huitinga, I. (2017). Gene Expression Profiling of
628 Multiple Sclerosis Pathology Identifies Early Patterns of Demyelination Surrounding Chronic
629 Active Lesions. *Front Immunol* 8, 1810.
- 630 Hicks, S.C., Townes, F.W., Teng, M., and Irizarry, R.A. (2017). Missing data and technical
631 variability in single-cell RNA-sequencing experiments. *Biostatistics* 19, 562-578.
- 632 Islam, S., Zeisel, A., Joost, S., La Manno, G., Zajac, P., Kasper, M., Lönnerberg, P., and Linnarsson,
633 S. (2014). Quantitative single-cell RNA-seq with unique molecular identifiers. *Nat Methods*
634 11, 163-166.
- 635 Jakel, S., Agirre, E., Mendanha Falcao, A., Van Bruggen, D., Lee, K.W., Knuesel, I., Malhotra, D.,
636 Ffrench-Constant, C., Williams, A., and Castelo-Branco, G. (2019). Altered human
637 oligodendrocyte heterogeneity in multiple sclerosis. *Nature* 566, 543-547.
- 638 Ke, R., Mignardi, M., Pacureanu, A., Svedlund, J., Botling, J., Wählby, C., and Nilsson, M. (2013).
639 In situ sequencing for RNA analysis in preserved tissue and cells. *Nat Methods* 10, 857-860.
- 640 Kinter, J., Zeis, T., and Schaeren-Wiemers, N. (2008). RNA profiling of MS brain tissues. *Int MS J*
641 15, 51-58.
- 642 Kulkarni, M.M. (2011). Digital Multiplexed Gene Expression Analysis Using the NanoString
643 nCounter System. *Current Protocols in Molecular Biology* 94, 25B.10.21-25B.10.17.
- 644 Lake, B.B., Chen, S., Sos, B.C., Fan, J., Kaeser, G.E., Yung, Y.C., Duong, T.E., Gao, D., Chun, J.,
645 Kharchenko, P.V., and Zhang, K. (2018). Integrative single-cell analysis of transcriptional
646 and epigenetic states in the human adult brain. *Nat Biotechnol* 36, 70-80.
- 647 Lassmann, H., Raine, C.S., Antel, J., and Prineas, J.W. (1998). Immunopathology of multiple
648 sclerosis: report on an international meeting held at the Institute of Neurology of the
649 University of Vienna. *J Neuroimmunol* 86, 213-217.
- 650 Lee, J.H., Daugharthy, E.R., Scheiman, J., Kalhor, R., Yang, J.L., Ferrante, T.C., Terry, R., Jeanty,
651 S.S., Li, C., Amamoto, R., Peters, D.T., Turczyk, B.M., Marblestone, A.H., Inverso, S.A.,
652 Bernard, A., Mali, P., Rios, X., Aach, J., and Church, G.M. (2014). Highly multiplexed
653 subcellular RNA sequencing in situ. *Science* 343, 1360-1363.
- 654 Lindberg, R.L., De Groot, C.J., Certa, U., Ravid, R., Hoffmann, F., Kappos, L., and Leppert, D.
655 (2004). Multiple sclerosis as a generalized CNS disease--comparative microarray analysis of
656 normal appearing white matter and lesions in secondary progressive MS. *J Neuroimmunol*
657 152, 154-167.
- 658 Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober,
659 S., Cannella, B., Allard, J., Klonowski, P., Austin, A., Lad, N., Kaminski, N., Galli, S.J.,
660 Oksenberg, J.R., Raine, C.S., Heller, R., and Steinman, L. (2002). Gene-microarray analysis
661 of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.
662 *Nat Med* 8, 500-508.
- 663 Lubeck, E., Coskun, A.F., Zhiyentayev, T., Ahmad, M., and Cai, L. (2014). Single-cell in situ RNA
664 profiling by sequential hybridization. *Nat Methods* 11, 360-361.

Running title: Pathology at single cell resolution

- 665 Lundin, E., Wu, C., Widmark, A., Behm, M., Hjerling-Leffler, J., Daniel, C., Öhman, M., and
666 Nilsson, M. (2020). Spatiotemporal mapping of RNA editing in the developing mouse brain
667 using in situ sequencing reveals regional and cell-type-specific regulation. *BMC Biol* 18, 6.
- 668 Ly, L., Barnett, M.H., Zheng, Y.Z., Gulati, T., Prineas, J.W., and Crossett, B. (2011). Comprehensive
669 Tissue Processing Strategy for Quantitative Proteomics of Formalin-fixed Multiple Sclerosis
670 Lesions. *Journal of Proteome Research* 10, 4855-4868.
- 671 Lynch, J., Peeling, J., Auty, A., and Sutherland, G.R. (1993). Nuclear magnetic resonance study of
672 cerebrospinal fluid from patients with multiple sclerosis. *Can J Neurol Sci* 20, 194-198.
- 673 Ma, S., Zhang, B., Lafave, L., Chiang, Z., Hu, Y., Ding, J., Brack, A., Kartha, V.K., Law, T., Lareau,
674 C., Hsu, Y.-C., Regev, A., and Buenrostro, J.D. (2020). Chromatin potential identified by
675 shared single cell profiling of RNA and chromatin. *bioRxiv*, 2020.2006.2017.156943.
- 676 Macchi, M., Magalon, K., Zimmer, C., Peeva, E., El Waly, B., Brousse, B., Jaekel, S., Grobe, K.,
677 Kiefer, F., Williams, A., Cayre, M., and Durbec, P. (2020). Mature oligodendrocytes
678 bordering lesions limit demyelination and favor myelin repair via heparan sulfate production.
679 *eLife* 9, e51735.
- 680 Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A.R.,
681 Kamitaki, N., Martersteck, E.M., Trombetta, J.J., Weitz, D.A., Sanes, J.R., Shalek, A.K.,
682 Regev, A., and Mccarroll, S.A. (2015). Highly Parallel Genome-wide Expression Profiling of
683 Individual Cells Using Nanoliter Droplets. *Cell* 161, 1202-1214.
- 684 Marisca, R., Hoche, T., Agirre, E., Hoodless, L.J., Barkey, W., Auer, F., Castelo-Branco, G., and
685 Czopka, T. (2020). Functionally distinct subgroups of oligodendrocyte precursor cells
686 integrate neural activity and execute myelin formation. *Nat Neurosci* 23, 363-374.
- 687 Marques, S., Zeisel, A., Codeluppi, S., Van Bruggen, D., Mendanha Falcao, A., Xiao, L., Li, H.,
688 Haring, M., Hochgerner, H., Romanov, R.A., Gyllborg, D., Munoz Manchado, A., La Manno,
689 G., Lonnerberg, P., Floriddia, E.M., Rezayee, F., Ernfors, P., Arenas, E., Hjerling-Leffler, J.,
690 Harkany, T., Richardson, W.D., Linnarsson, S., and Castelo-Branco, G. (2016).
691 Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system.
692 *Science* 352, 1326-1329.
- 693 Masuda, T., Sankowski, R., Staszewski, O., Bottcher, C., Amann, L., Sagar, Scheiwe, C., Nessler, S.,
694 Kunz, P., Van Loo, G., Coenen, V.A., Reinacher, P.C., Michel, A., Sure, U., Gold, R., Grun,
695 D., Priller, J., Stadelmann, C., and Prinz, M. (2019). Spatial and temporal heterogeneity of
696 mouse and human microglia at single-cell resolution. *Nature* 566, 388-392.
- 697 Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J.Z., Menon, M., He,
698 L., Abdurrob, F., Jiang, X., Martorell, A.J., Ransohoff, R.M., Hafler, B.P., Bennett, D.A.,
699 Kellis, M., and Tsai, L.H. (2019). Single-cell transcriptomic analysis of Alzheimer's disease.
700 *Nature* 570, 332-337.
- 701 Maynard, K.R., Collado-Torres, L., Weber, L.M., Uytingco, C., Barry, B.K., Williams, S.R.,
702 Catallini, J.L., Tran, M.N., Besich, Z., Tippi, M., Chew, J., Yin, Y., Kleinman, J.E., Hyde,
703 T.M., Rao, N., Hicks, S.C., Martinowich, K., and Jaffe, A.E. (2020). Transcriptome-scale
704 spatial gene expression in the human dorsolateral prefrontal cortex. *bioRxiv*,
705 2020.2002.2028.969931.
- 706 Melief, J., Orre, M., Bossers, K., Van Eden, C.G., Schuurman, K.G., Mason, M.R.J., Verhaagen, J.,
707 Hamann, J., and Huitinga, I. (2019). Transcriptome analysis of normal-appearing white

Running Title: Pathology at single cell resolution

- matter reveals cortisol- and disease-associated gene expression profiles in multiple sclerosis. *Acta Neuropathol Commun* 7, 60.
- Mills, J.D., Chen, J., Kim, W.S., Waters, P.D., Prabowo, A.S., Aronica, E., Halliday, G.M., and Janitz, M. (2015). Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in the cortical white matter. *Neurogenetics* 16, 201-213.
- Mycko, M.P., Papoian, R., Boschert, U., Raine, C.S., and Selmaj, K.W. (2003). cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. *Brain* 126, 1048-1057.
- Nagy, C., Maitra, M., Tanti, A., Suderman, M., Thérout, J.-F., Davoli, M.A., Perlman, K., Yerko, V., Wang, Y.C., Tripathy, S.J., Pavlidis, P., Mechawar, N., Ragoussis, J., and Turecki, G. (2020). Single-nucleus transcriptomics of the prefrontal cortex in major depressive disorder implicates oligodendrocyte precursor cells and excitatory neurons. *Nature Neuroscience*.
- Park, C., Ponath, G., Levine-Ritterman, M., Bull, E., Swanson, E.C., De Jager, P.L., Segal, B.M., and Pitt, D. (2019). The landscape of myeloid and astrocyte phenotypes in acute multiple sclerosis lesions. *Acta Neuropathol Commun* 7, 130.
- Picelli, S. (2017). Single-cell RNA-sequencing: The future of genome biology is now. *RNA Biol* 14, 637-650.
- Picelli, S., Faridani, O.R., Bjorklund, A.K., Winberg, G., Sagasser, S., and Sandberg, R. (2014). Full-length RNA-seq from single cells using Smart-seq2. *Nat Protoc* 9, 171-181.
- Preissl, S., Fang, R., Huang, H., Zhao, Y., Raviram, R., Gorkin, D.U., Zhang, Y., Sos, B.C., Afzal, V., Dickel, D.E., Kuan, S., Visel, A., Pennacchio, L.A., Zhang, K., and Ren, B. (2018). Single-nucleus analysis of accessible chromatin in developing mouse forebrain reveals cell-type-specific transcriptional regulation. *Nat Neurosci* 21, 432-439.
- Ramaglia, V., Sheikh-Mohamed, S., Legg, K., Park, C., Rojas, O.L., Zandee, S., Fu, F., Ornatsky, O., Swanson, E.C., Pitt, D., Prat, A., Mckee, T.D., and Gommerman, J.L. (2019). Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry. *Elife* 8.
- Renthal, W., Boxer, L.D., Hrvatin, S., Li, E., Silberfeld, A., Nagy, M.A., Griffith, E.C., Vierbuchen, T., and Greenberg, M.E. (2018). Characterization of human mosaic Rett syndrome brain tissue by single-nucleus RNA sequencing. *Nature Neuroscience* 21, 1670-1679.
- Saelens, W., Cannoodt, R., Todorov, H., and Saeys, Y. (2019). A comparison of single-cell trajectory inference methods. *Nat Biotechnol* 37, 547-554.
- Satija, R., Farrell, J.A., Gennert, D., Schier, A.F., and Regev, A. (2015). Spatial reconstruction of single-cell gene expression data. *Nature biotechnology* 33, 495-502.
- Schirmer, L., Velmeshev, D., Holmqvist, S., Kaufmann, M., Werneburg, S., Jung, D., Vistnes, S., Stockley, J.H., Young, A., Steindel, M., Tung, B., Goyal, N., Bhaduri, A., Mayer, S., Engler, J.B., Bayraktar, O.A., Franklin, R.J.M., Haeussler, M., Reynolds, R., Schafer, D.P., Friese, M.A., Shiow, L.R., Kriegstein, A.R., and Rowitch, D.H. (2019). Neuronal vulnerability and multilineage diversity in multiple sclerosis. *Nature* 573, 75-82.
- Shah, S., Lubeck, E., Zhou, W., and Cai, L. (2016). In Situ Transcription Profiling of Single Cells Reveals Spatial Organization of Cells in the Mouse Hippocampus. *Neuron* 92, 342-357.
- Sinnamon, J.R., Torkenczy, K.A., Linhoff, M.W., Vitak, S.A., Mulqueen, R.M., Pliner, H.A., Trapnell, C., Steemers, F.J., Mandel, G., and Adey, A.C. (2019). The accessible chromatin landscape of the murine hippocampus at single-cell resolution. *Genome Res* 29, 857-869.

- 751 Stahl, P.L., Salmen, F., Vickovic, S., Lundmark, A., Navarro, J.F., Magnusson, J., Giacomello, S.,
752 Asp, M., Westholm, J.O., Huss, M., Mollbrink, A., Linnarsson, S., Codeluppi, S., Borg, A.,
753 Ponten, F., Costea, P.I., Sahlen, P., Mulder, J., Bergmann, O., Lundeberg, J., and Frisen, J.
754 (2016). Visualization and analysis of gene expression in tissue sections by spatial
755 transcriptomics. *Science* 353, 78-82.
- 756 Svensson, V., Vento-Tormo, R., and Teichmann, S.A. (2018). Exponential scaling of single-cell
757 RNA-seq in the past decade. *Nat Protoc* 13, 599-604.
- 758 Tajouri, L., Mellick, A.S., Ashton, K.J., Tannenberg, A.E., Nagra, R.M., Tourtellotte, W.W., and
759 Griffiths, L.R. (2003). Quantitative and qualitative changes in gene expression patterns
760 characterize the activity of plaques in multiple sclerosis. *Brain Res Mol Brain Res* 119, 170-
761 183.
- 762 Tang, F., Barbacioru, C., Wang, Y., Nordman, E., Lee, C., Xu, N., Wang, X., Bodeau, J., Tuch, B.B.,
763 Siddiqui, A., Lao, K., and Surani, M.A. (2009). mRNA-Seq whole-transcriptome analysis of a
764 single cell. *Nat Methods* 6, 377-382.
- 765 Thrupp, N., Frigerio, C.S., Wolfs, L., Skene, N.G., Poovathingal, S., Fourne, Y., Matthews, P.M.,
766 Theys, T., Mancuso, R., De Strooper, B., and Fiers, M. (2020). Single nucleus sequencing
767 fails to detect microglial activation in human tissue. *bioRxiv*, 2020.2004.2013.035386.
- 768 Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N.J., Livak, K.J.,
769 Mikkelsen, T.S., and Rinn, J.L. (2014). The dynamics and regulators of cell fate decisions are
770 revealed by pseudotemporal ordering of single cells. *Nature biotechnology* 32, 381-386.
- 771 Van Der Poel, M., Ulas, T., Mizee, M.R., Hsiao, C.C., Miedema, S.S.M., Adelia, Schuurman, K.G.,
772 Helder, B., Tas, S.W., Schultze, J.L., Hamann, J., and Huitinga, I. (2019). Transcriptional
773 profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-
774 associated changes. *Nat Commun* 10, 1139.
- 775 Velmeshev, D., Schirmer, L., Jung, D., Haeussler, M., Perez, Y., Mayer, S., Bhaduri, A., Goyal, N.,
776 Rowitch, D.H., and Kriegstein, A.R. (2019). Single-cell genomics identifies cell type-specific
777 molecular changes in autism. *Science* 364, 685-689.
- 778 Vieth, B., Parekh, S., Ziegenhain, C., Enard, W., and Hellmann, I. (2019). A Systematic Evaluation
779 of Single Cell RNA-Seq Analysis Pipelines. *bioRxiv*, 583013.
- 780 Vistain, L., Phan, H.V., Jordi, C., Chen, M., Reddy, S.T., and Tay, S. (2020). Quantification of
781 proteins, protein complexes and mRNA in single cells by proximity-sequencing. *bioRxiv*,
782 2020.2005.2015.098780.
- 783 Wang, X., Allen, W.E., Wright, M.A., Sylwestrak, E.L., Samusik, N., Vesuna, S., Evans, K., Liu, C.,
784 Ramakrishnan, C., Liu, J., Nolan, G.P., Bava, F.A., and Deisseroth, K. (2018). Three-
785 dimensional intact-tissue sequencing of single-cell transcriptional states. *Science* 361.
- 786 Werner, H.B., and Jahn, O. (2010). Myelin matters: proteomic insights into white matter disorders.
787 *Expert Review of Proteomics* 7, 159-164.
- 788 Wheeler, M.A., Clark, I.C., Tjon, E.C., Li, Z., Zandee, S.E.J., Couturier, C.P., Watson, B.R., Scalisi,
789 G., Alkwai, S., Rothhammer, V., Rotem, A., Heyman, J.A., Thaploo, S., Sanmarco, L.M.,
790 Ragoussis, J., Weitz, D.A., Petrecca, K., Moffitt, J.R., Becher, B., Antel, J.P., Prat, A., and
791 Quintana, F.J. (2020). MAFG-driven astrocytes promote CNS inflammation. *Nature* 578,
792 593-599.

- Whitney, L.W., Becker, K.G., Tresser, N.J., Caballero-Ramos, C.I., Munson, P.J., Prabhu, V.V., Trent, J.M., Mcfarland, H.F., and Biddison, W.E. (1999). Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. *Ann Neurol* 46, 425-428.
- Whitney, L.W., Ludwin, S.K., Mcfarland, H.F., and Biddison, W.E. (2001). Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. *J Neuroimmunol* 121, 40-48.
- Wu, H., Kirita, Y., Donnelly, E.L., and Humphreys, B.D. (2019). Advantages of Single-Nucleus over Single-Cell RNA Sequencing of Adult Kidney: Rare Cell Types and Novel Cell States Revealed in Fibrosis. *J Am Soc Nephrol* 30, 23-32.
- Zeis, T., Graumann, U., Reynolds, R., and Schaeren-Wiemers, N. (2008). Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. *Brain* 131, 288-303.
- Zeis, T., Howell, O.W., Reynolds, R., and Schaeren-Wiemers, N. (2018). Molecular pathology of Multiple Sclerosis lesions reveals a heterogeneous expression pattern of genes involved in oligodendroglioneogenesis. *Exp Neurol* 305, 76-88.
- Zeisel, A., Munoz-Manchado, A.B., Codeluppi, S., Lonnerberg, P., La Manno, G., Jureus, A., Marques, S., Munguba, H., He, L., Betsholtz, C., Rolny, C., Castelo-Branco, G., Hjerling-Leffler, J., and Linnarsson, S. (2015). Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science* 347, 1138-1142.
- Zheng, G.X., Terry, J.M., Belgrader, P., Ryvkin, P., Bent, Z.W., Wilson, R., Ziraldo, S.B., Wheeler, T.D., McDermott, G.P., Zhu, J., Gregory, M.T., Shuga, J., Montesclaros, L., Underwood, J.G., Masquelier, D.A., Nishimura, S.Y., Schnall-Levin, M., Wyatt, P.W., Hindson, C.M., Bharadwaj, R., Wong, A., Ness, K.D., Beppu, L.W., Deeg, H.J., Mcfarland, C., Loeb, K.R., Valente, W.J., Ericson, N.G., Stevens, E.A., Radich, J.P., Mikkelsen, T.S., Hindson, B.J., and Bielas, J.H. (2017). Massively parallel digital transcriptional profiling of single cells. *Nat Commun* 8, 14049.
- Zhong, S., Ding, W., Sun, L., Lu, Y., Dong, H., Fan, X., Liu, Z., Chen, R., Zhang, S., Ma, Q., Tang, F., Wu, Q., and Wang, X. (2020). Decoding the development of the human hippocampus. *Nature* 577, 531-536.
- Zhou, Y., Song, W.M., Andhey, P.S., Swain, A., Levy, T., Miller, K.R., Poliani, P.L., Cominelli, M., Grover, S., Gilfillan, S., Cella, M., Ulland, T.K., Zaitsev, K., Miyashita, A., Ikeuchi, T., Sainouchi, M., Kakita, A., Bennett, D.A., Schneider, J.A., Nichols, M.R., Beausoleil, S.A., Ulrich, J.D., Holtzman, D.M., Artyomov, M.N., and Colonna, M. (2020). Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. *Nat Med* 26, 131-142.

828

829 10 Figure legends

830 **Figure 1: Schematic overview of the workflow of common bulk approaches to address human**
831 **pathology.** (A) Standard workflow of bulk RNA-sequencing: the entirety of mRNA/RNA is isolated
832 from a tissue/cell type of interest and prepared for next generation sequencing, which is followed by
833 bioinformatics data analysis. (B) Standard workflow of bulk proteomics: the entirety of proteins is
834 isolated from a tissue/cell type of interest and prepared for mass spectrometry, which is followed by
835 bioinformatics data analysis. (C) Standard workflow of bulk metabolomics: the entirety of metabolites

is isolated from a tissue/cell type of interest and prepared for mass spectrometry, which is followed by bioinformatics data analysis. In all approaches (A-C) the information about the cell of origin and the spatial distribution are lost.

Figure 2: Schematic overview of the workflow of common single cell/nuclei (sc/sn) approaches to address human pathology. (A) Standard workflow of droplet-based sc/sn RNA-sequencing: tissue is dissociated into a single cell/nuclei suspension and the mRNA of each cell is captured and barcoded individually and prepared for next generation sequencing, which is followed by bioinformatics data analysis. This can be done for up to ten thousands of cells. (B) Standard workflow of well-based sc/sn RNA-sequencing: tissue is dissociated into a single cell/nuclei suspension and the cells are captured in individual wells where each cell is prepared for next generation sequencing, which is followed by bioinformatics data analysis. This is usually done for less than 1000 cells. (C) Standard workflow of droplet-based ATAC-seq: tissue is dissociated into a single cell/nuclei suspension and the open chromatin regions of each cell are cut and barcoded individually and prepared for next generation sequencing, which is followed by bioinformatics data analysis. This can be done for up to ten thousands of cells. In all approaches (A-C) the information about the cell of origin is maintained, but the spatial distribution is lost.

Figure 3: Schematic overview of an imaginative holistic workflow of common single cell/nuclei (sc/sn) and validation approaches to address human pathology. Tissue is dissociated into a single cell/nuclei suspension and sc/snRNA-seq, sc/snATAC-seq, scCyTOF, scProteomics and scMetabolomics are performed in parallel on the same tissue source with their respective workflows. After individual and comparative/integrated bioinformatics data analysis, the results are validated, ideally on a different tissue source by standard immunohistochemistry (IHC), in-situ hybridization (ISH) and other high throughput multiplexed techniques (100-1000 genes/proteins of interest) where IHC and ISH can be combined. With such a possible workflow, first the information about the cell of origin is maintained, and with the validation techniques, the spatial resolution can be analyzed as well. This holistic approach would allow to thoroughly exploring human pathology from different angles to gain deeper information.

Figure 4: Summary of the biological findings in Multiple Sclerosis (MS) that were gained through advances in technology. Classical histology has helped to classify MS lesions based on their immunological status. The development of bulk transcriptomic approaches has helped to unravel many transcriptional pathways that are changed in MS, with the most important common theme being inflammation. More recent studies using sc/snRNA-seq has started to unravel cellular heterogeneity and changes in the representation of these cells in disease. Combining different sc/sn approaches and using spatial technologies in the future will help to deepen our understanding of the functionality of the heterogeneous clusters and the underlying pathological mechanisms.

Figure 1.JPEG






Figure 2.JPEG

A droplet-based
scRNA-seq



B well-based
scRNA-seq



C scATAC-seq





Figure 3.JPEG



Technological advances in MS pathology over time

